Results 131 to 140 of about 11,258 (167)

Characterization of a Monoclonal Antibody Specific for Novel Bcr/Abl Out-of-Frame Fusion Proteins

Hybridoma, 2011
The new tumor-specific antigens Bcr/Abl-OOF, identified in Philadelphia chromosome (Ph)-positive leukemia cells, are derived from an alternative splicing event involving BCR exons 1, 13, or 14 and ABL exons 4 and 5. The COOH-terminus of these transcription products contain an amino acid portion derived from an out-of-frame (OOF) reading of the ABL gene;
C. Casnici, G. Volpe, K. Crotta, C. Panuzzo, D. Lattuada, C. A. Cabras, R. Longhi, G. Saglio, O. Marelli   +8 more
openaire   +4 more sources

Targeting the Kinase Activity of the BCR-ABL Fusion Protein in Patients with Chronic Myeloid Leukemia

Current Molecular Medicine, 2005
Imatinib mesylate is a major advance in the therapy of patients with chronic myelogenous leukemia (CML). Imatinib mesylate binds to the inactive conformation of BCR-ABL tyrosine kinase suppressing the Philadelphia chromosome positive clone in CML. Clinical studies have yielded impressive results in all phases of CML.
Francis J, Giles, Jorge E, Cortes, Hagop M, Kantarjian   +2 more
openaire   +2 more sources

Detection of BCR-ABL fusion proteins in patients with leukemia using a cytometric bead array

Leukemia & Lymphoma, 2011
Rapid and accurate detection of BCR-ABL fusion proteins is vital for the diagnosis and classification of leukemias, especially chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Recently, the cytometric bead array (CBA) system has been used to identify BCR-ABL proteins in leukemic cell lysates.
Wu, Yujie, Zhu, Yu, Qian, Sixuan, Wang, Li, Liu, Peng, Ge, Zeng, Zhang, Sujiang, Li, Jianyong   +7 more
openaire   +2 more sources

Flow Cytometry Detection of BCR-ABL Fusion Proteins in Leukemia Patients- An Indian Experience.

Blood, 2009
Abstract Abstract 4710 Background The BCR-ABL fusion gene results from the translocation t(9;22). It is the hallmark of chronic myeloid leukemia (CML) and is present in a poor risk subgroup of precursor B cell Acute Lymphoblastic Leukemia(ALL),which represents 25 to 30% of adult ALL and
Soma Mukhopadhyay, Ujjal Kanti Roy, Ritwik Pandey, Pinaki Gupta, Jayasri Basak, Sanjay Sarkar, Ashis Mukhopadhyay, Haemato   +6 more
openaire   +1 more source

Differential signaling through p190 and p210 BCR-ABL fusion proteins revealed by interactome and phosphoproteome analysis

Leukemia, 2017
Two major types of leukemogenic BCR-ABL fusion proteins are p190BCR-ABLand p210BCR-ABL. Although the two fusion proteins are closely related, they can lead to different clinical outcomes. A thorough understanding of the signaling programs employed by these two fusion proteins is necessary to explain these clinical differences.
J A, Cutler, R, Tahir, S K, Sreenivasamurthy, C, Mitchell, S, Renuse, R S, Nirujogi, A H, Patil, M, Heydarian, X, Wong, X, Wu, T-C, Huang, M-S, Kim, K L, Reddy, A, Pandey   +13 more
openaire   +2 more sources

Comparative Study of Molecular Interactions of Thymol and Imatinib with BCR-ABL Fusion Protein In-Silico for the Selective Anti-CML Activity of Thymol

CARDIOMETRY, 2023
Aim: To study the comparative molecular interactions of Thymol and Imatinib with the active sites of Breakpoint Cluster Region (BCR)-Abelson (ABL) fusion protein using molecular docking analysis for the selective anti-Chronic myeloid leukemia (CML) activity.
R.M.R. Charan, D. Lokesh
openaire   +1 more source

Comparative Study of Molecular Interaction of Quercetin and Imatinib with BCR-ABL Fusion Protein In-Silico for the Selective Anti-CML Activity of Quercetin

CARDIOMETRY, 2023
Aim: To study the comparative molecular interactions of Quercetin and Imatinib with the active sites of Breakpoint Cluster Region (BCR)-Abelson (ABL) fusion protein using molecular docking analysis for the selective anti-Chronic myeloid leukemia (CML) activity.
R.M.R. Charan, G. Reddypriya
openaire   +1 more source

[Preparation and identification of rabbit polyclonal antibody against BCR-ABL b3a2 fusion protein].

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology, 2021
Objective To prepare and identify rabbit anti-breakpoint cluster region-Abelson leukemia virus oncogene (BCR-ABL) b3a2 subtype polyclonal antibody. Methods A peptide containing the fusion sequence of the b3a2 subtype BCR-ABL fusion protein was designed and synthesized with the purity higher than 90%. The fusion polypeptide was coupled to Keyhole Limpet
Xiangning, Li, Jiayao, Qu, Jing, Jiang, Li, Wang, Dixian, Luo, Jia, Li, Lili, Duan, Rongzhang, He, Zheng, Hu   +8 more
openaire   +1 more source

TAT-CC fusion protein depresses the oncogenicity of BCR-ABL in vitro and in vivo through interrupting its oligomerization

Amino Acids, 2012
Chronic myeloid leukemia (CML) is a clonal hematologic malignancy characterized by the BCR-ABL protein. BCR-ABL is a constitutively active tyrosine kinase and plays a critical role in the pathogenesis of CML. Imatinib mesylate, a selective tyrosine kinase inhibitor, is effective in CML, but drug resistance and relapse occur. The coiled-coil (CC) domain
Zheng-Lan, Huang, Miao, Gao, Mao-Sheng, Ji, Kun, Tao, Qing, Xiao, Liang, Zhong, Jian-Ming, Zeng, Wen-Li, Feng   +7 more
openaire   +2 more sources

Immunologic Evaluation of Peptides Derived From BCR/ABL-Out-of-Frame Fusion Protein in HLA A2.1 Transgenic Mice

Journal of Immunotherapy, 2012
Philadelphia chromosome-positive chronic myelogenous leukemia and acute lymphocytic leukemia express, besides the main BCR/ABL transcripts, novel BCR/ABL transcripts derived from alternative splicing between BCR exons 1, 13, or 14 with ABL exons 4 and 5. Their translational products present at C-terminus an amino acid portion derived from out-of-frame (
C. Casnici, G. Volpe, K. Crotta, D. Lattuada, G. Saglio, O. Marelli   +5 more
openaire   +2 more sources